Skip to content
value.today

Hyperion Defi, Inc.

HYPD
$52 Mmarket cap on Oct 9, 2026-36.3% since Jan 2024
Compare
World rank
#21,121
Revenue
$2 M
For year ending December-2025
value.today research
Net income
$-20 M
-985.0% margin
value.today research
Employees
—

Hyperion Defi, Inc. in brief

Hyperion Defi, Inc. is a listed company in the Biotechnology industry, based in the USA. Its market value was $52 M on 9 October 2026, which makes it the 21,121st largest listed company in the world and the 3,840th largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $20 M. Its largest business segments by sales in 2025 were Digital Assets (98%) and Ophthalmic Technology (2%). Its shares trade under the symbol HYPD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Hyperion Defi, Inc.

We were organized as a corporation under the laws of the State of Florida on March 12, 2014 under the name “PGP Holdings V, Inc.” On May 5, 2014, we changed our name to Eyenovia, Inc. On October 6, 2014, we reincorporated in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation. On July 1, 2025, we changed our name to Hyperion DeFi, Inc. Our principal executive office is located at 23461 S. Pointe Drive, Suite 390, Laguna Hills, CA 92653, and our telephone number is (833) 393-6684. We maintain a website at www.hyperiondefi.com, to which we regularly post copies of our press releases as well as additional information about us. The information contained on, or that can be accessed through, our website is not a part of this report. We have included our website address in this report solely as an inactive textual reference.

Hyperion Defi, Inc. timeline

5 events, 2016–2025
  1. 2016
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2018
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 🔔
    Initial public offering as Eyenovia, Inc.
    Final prospectus filed with the SEC on 25 January 2018; shares registered for exchange trading on 24 January 2018.
  6. 2021
  7. 💰
    Record revenue of $14 million
    FY2021, the highest of the 5 years on record.
  8. 2025
  9. ✎
    Renamed Hyperion Defi, Inc.
    Formerly Eyenovia, Inc..

Events of Hyperion Defi, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$41 M$82 M$122 M$163 M2020202120222023202420252026

World rank over time

▼ down 1,279 places since 2020
2020-01-01: #19931#19,93120202021-01-01: #16587#16,58720212022-01-07: #22735#22,73520222022-12-25: #24431#24,43120222023-07-30: #22821#22,82120232024-01-05: #22433#22,43320242026-10-09: #21210#21,2102026

Rank in USA: #3,857 (Jan 2020) · #3,432 (Jan 2021) · #4,391 (Jan 2022) · #4,683 (Dec 2022) · #4,401 (Jul 2023) · #3,836 (Jan 2024) · #3,820 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
26.1×
Price / book
1.3×
Free cash flow yield
-58.0%
Net margin
-985.0%
Operating margin
-2336.0%
Return on equity
-48.0%
Liabilities / assets
20.7%
Revenue growth
+1250.0%
R&D / revenue
235.8%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-17M—FY18Fiscal year ending Dec 2019: revenue —, net income $-21M—FY19Fiscal year ending Dec 2020: revenue $2M, net income $-20M$2MFY20Fiscal year ending Dec 2021: revenue $14M, net income $-13M$14MFY21Fiscal year ending Dec 2022: revenue —, net income $-28M—FY22Fiscal year ending Dec 2023: revenue $0M, net income $-27M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-50M$0MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-45M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M+1250.0%$-47M$-45M-5593.8%
Dec 2024$0M—$-49M$-50M-83033.3%
Dec 2023$0M—$-25M$-27M—
Dec 2022——$-27M$-28M—
Dec 2021$14M+600.0%$-13M$-13M-91.3%
Dec 2020$2M—$-20M$-20M-988.5%
Dec 2019——$-21M$-21M—
Dec 2018——$-17M$-17M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-15M——$-9.40—
Dec 2024$-30M$0M$-30M$-59.81—
Dec 2023$-24M$3M$-27M$-53.15—
Dec 2022$-25M$1M$-26M$-0.83—
Dec 2021$-21M$1M$-22M$-0.49—
Dec 2020$-6M$0M$-7M$-0.94—
Dec 2019$-19M$0M$-19M$-1.47—
Dec 2018$-13M$0M$-13M$-1.82—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-20M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-3M$0MMar ’25Three months to Jun 2025: revenue —, net income $-9M—Jun ’25Three months to Sep 2025: revenue $0M, net income $7M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-40M—Dec ’25Three months to Mar 2026: revenue $0M, net income $9M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $31M$0MJun ’26Three months to Sep 2026: revenue $1M, net income $40M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (+170.0% on a year earlier), net income $40M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Hyperion Defi, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$2 M
Operating income
$-47 M
Net income
$-20 M

For year ending December-2025

Balance sheet

Total assets
$52 M
Total liabilities
$11 M
Total equity
$41 M

As of December-2025

Top 35 institutional investors in Hyperion Defi, Inc.#

As of Sep 30, 2026
35 institutions held 3.0 M shares (about 19.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 15.4%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Hyperion Defi, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC575,568+108,770 (+23.30%)3.70%$2 MNov 13, 2026
2Franklin Templeton Inc392,639-3,300 (-0.83%)2.53%$1 MNov 12, 2026
3Morgan Stanley300,046+62,060 (+26.08%)1.93%$1 MNov 13, 2026
4Arrington Capital Management, LLC280,777-17,000 (-5.71%)1.81%$1 MNov 16, 2026
5Geode Capital Management, LLC166,570+35,863 (+27.44%)1.07%$1 MNov 6, 2026
6Almanack Investment Partners, LLC.161,323-7,690 (-4.55%)1.04%$1 MNov 3, 2026
7Jane Street Group, LLC148,363+20,872 (+16.37%)0.95%$1 MNov 12, 2026
8Oppenheimer & Co Inc127,703+1,338 (+1.06%)0.82%$0 MOct 26, 2026
9BlackRock, Inc.122,865+8,465 (+7.40%)0.79%$0 MNov 13, 2026
10Marshall Wace, LLP114,285New0.74%$0 MNov 13, 2026
11UBS Group AG101,438+68,259 (+205.73%)0.65%$0 MNov 10, 2026
12Citadel Advisors LLC77,106+20,807 (+36.96%)0.50%$0 MNov 16, 2026
13Vanguard Fiduciary Trust Co74,4550 (0.00%)0.48%$0 MNov 13, 2026
14State Street Corp54,3570 (0.00%)0.35%$0 MNov 12, 2026
15Intesa Sanpaolo S.p.A.53,000New0.34%$0 MNov 16, 2026
16Invesco Ltd.47,988New0.31%$0 MNov 12, 2026
17Accurate Wealth Management, LLC35,430New0.23%$0 MOct 20, 2026
18Northern Trust Corp32,086+1,190 (+3.85%)0.21%$0 MNov 16, 2026
19Price T Rowe Associates Inc /MD/20,5000 (0.00%)0.13%$0 MNov 16, 2026
20Peak6 LLC20,0000 (0.00%)0.13%$0 MNov 13, 2026
21R Squared Ltd19,355New0.12%$0 MNov 6, 2026
22XTX Topco Ltd12,782+493 (+4.01%)0.08%$0 MNov 16, 2026
23Jpmorgan Chase & Co12,308-3,799 (-23.59%)0.08%$0 MNov 12, 2026
24Concurrent Investment Advisors, LLC11,307New0.07%$0 MOct 16, 2026
25Nations Financial Group Inc, /ia/ /adv11,1250 (0.00%)0.07%$0 MNov 5, 2026
Show all 35: investors 26 to 35
Institutional investors 26 to 35 in Hyperion Defi, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Sanctuary Advisors, LLC10,8000 (0.00%)0.07%$0 MNov 13, 2026
27Vanguard Global Advisers, LLC8,695+8,596 (+8682.83%)0.06%$0 MNov 13, 2026
28Tower Research Capital LLC (TRC)4,656+3,804 (+446.48%)0.03%$0 MNov 16, 2026
29SBI Securities Co., Ltd.1,584+365 (+29.94%)0.01%$0 MOct 22, 2026
30Wells Fargo & Company/mn1,233+3 (+0.24%)0.01%$0 MNov 16, 2026
31Royal Bank Of Canada419New0.00%$0 MNov 16, 2026
32Caitong International Asset Management Co., Ltd67+63 (+1575.00%)0.00%$0 MOct 29, 2026
33BNP Paribas Financial Markets540 (0.00%)0.00%$0 MNov 12, 2026
34Barclays PLC3-1,804 (-99.83%)0.00%$0 MNov 6, 2026
35Group One Trading LLC10 (0.00%)0.00%$0 MNov 10, 2026

Mutual funds holding Hyperion Defi, Inc.#

12 funds hold shares worth $3 M (about 6.3% of the company). Since their previous reports 11 added shares and 1 sold, buying $3 M net.
Mutual funds holding Hyperion Defi, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Putnam Small Cap Value FundPutnam Investment Management, LLC286,628$1 M1.8%0.34%newMay 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.290,757$1 M1.9%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.176,041$1 M1.1%<0.01%+109%Jun 30, 2026
🇺🇸 Putnam VT Small Cap Value FundPutnam Investment Management, LLC109,172$0 M0.70%0.28%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC37,727$0 M0.24%<0.01%+23%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors33,999$0 M0.22%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.20,500$0 M0.13%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC13,409$0 M0.09%<0.01%+45%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC10,255$0 M0.07%<0.01%+29%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC3,922$0 M0.03%<0.01%+354%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,293$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC212$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Hyperion Defi, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$641 K
13 purchases, 5 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$641 K
open market only
Insiders on file
24
since
$1000 K$0Dec 2023: bought $7 K (1 trades), sold $0 (0 trades)Dec 23Mar 2024: bought $176 K (3 trades), sold $0 (0 trades)MarJul 2024: bought $1000 K (1 trades), sold $0 (0 trades)JulAug 2024: bought $43 K (2 trades), sold $0 (0 trades)AugDec 2025: bought $611 K (9 trades), sold $0 (0 trades)DecJun 2026: bought $30 K (4 trades), sold $0 (0 trades)Jun
Bought (open market)Sold (open market)Hover a month for the totals
Hyperion Defi, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David R. KnoxChief Financial OfficerShares withheld for tax-19,563——287,556Form 4
filed Hyunsu JungSee Remarks, DirectorShares withheld for tax-40,000——1.35 MForm 4
filed Rachel JacobsonDirectorGrant or award+58,917——115,218Form 4
filed Ellen R. StrahlmanDirectorGrant or award+58,917——150,078Form 4
filed Michael S. GeltzeilerDirectorGrant or award+58,917——146,932Form 4
filed Happy David WaltersDirectorGrant or award+58,917——170,847Form 4
filed Hyunsu JungSee Remarks, DirectorBuy+500$3.640$2 K1.39 MForm 4
filed Hyunsu JungSee Remarks, DirectorBuy+500$3.680$2 K1.39 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Hyperion Defi, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.2 M
14.3% of shares · 5.11 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-80 reverse split

Trading halts

  • 2025-07-03 13:31 UTC, code LUDP, resumed 13:36 UTC
  • 2025-06-30 13:34 UTC, code LUDP, resumed 13:39 UTC
  • 2025-06-17 19:00 UTC, code LUDP, resumed 19:05 UTC
  • 2025-03-20 10:55 UTC, code T3, resumed 11:30 UTC
  • 2025-02-01 00:50 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 78 shares at $3.37
  • : 1,320 shares at $3.82
  • : 12,913 shares at $3.73
  • : 8,491 shares at $3.62
  • : 2,697 shares at $3.41

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Hyperion Defi, Inc. scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 9, 2026.

  • Valuation1 of 3
    • –P/E below its peers' medianNo P/E on file.
    • ✓Price to book below its peers' median1.3×Price to book 1.3× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median26.1×Price to sales 26.1× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-58.0%Free cash flow is -58.0% of the market value.
    • –Earnings yield above the 10-year Treasury yieldNo P/E on file.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-9.40 vs -59.81Diluted EPS -9.40 in fiscal 2025 against -59.81 the year before (report's currency).
    • ✗Net income higher than five years earlier-$45 M-$45 M in fiscal 2025 against -$20 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$45 MNet income -$45 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-324.1%-324.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities2.7×Current ratio 2.69 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-123.0×Operating income -123.0 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-6.44Z-score -6.44 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Hyperion Defi, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Hyperion Defi, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.80.10.0—142.0————
Cost of revenue0.33.90.0r—1.60.8————
Gross profit0.5−3.9−0.0—121.2————
Research and development1.914131315r13r14113.83.0
Selling, general and administrative171412———————
General and administrative——121411r7.6r7.26.11.30.6
Operating expenses474525r2725r2121175.13.5
Operating income−47−49−25−27−13r−20−21−17−5.1−3.5
Interest and finance income0.20.30.7—————0.00.0
Interest expense and finance costs1.62.52.41.40.40.00———
Other non-operating income (expense)1.4−1.1−1.9−1.1r0.2r—————
Income tax−0.0—————0000
Net income attributable to shareholders−45−50−27−28−13−20−21−17−5.1−3.5
Earnings per share, basic-9.40-59.81-53.15r-0.83-0.49-0.94-1.47-1.82-2.19-1.56
Earnings per share, diluted-9.40-59.81-53.15r-0.83-0.49-0.94-1.47-1.82-2.19-1.56
Shares, weighted average (basic)5.00.80.5r342621————
Shares, weighted average (diluted)5.00.80.5r342621149.52.32.3
Balance sheet
Cash and cash equivalents6.3r2.11523192814205.23.4
Inventory——0.1———————
Other current assets0.3r0.1r1.41.20.7r0.50.20.10.00.0
Current assets7.22.8212822r3314205.33.4
Property, plant and equipment——3.41.31.30.40.20.00.00.0
Right-of-use (leased) assets0.40.71.71.3——————
Other intangible assets——2.1———————
Total assets523.72931323415205.63.4
Accounts payable0.32.0r1.81.41.61.51.51.50.20.3
Current liabilities2.7169.54.511182.93.10.60.4
Lease liabilities (non-current)0.20.71.3r0.9——————
Total liabilities1117201411193.03.10.6—
Retained earnings−241−195−145−118−90−77−58−37−19−14
Shareholders' equity41−139.017201512175.13.0
Total liabilities and equity523.72931323415205.63.4
Shares outstanding8.71.50.6r37282517112.62.3
Cash-flow statement
Depreciation and amortization—1.10.80.30.20.10.00.00.00.0
Share-based compensation6.41.72.53.82.92.52.51.60.40.0
Cash from operating activities−15−30−24−25−21−6.4−19−13−4.7−3.2
Capital expenditure—−0.2−2.8−0.5−1.2−0.3−0.2−0.0−0.0−0.0
Intangible assets bought——−1.1———————
Cash from investing activities−72−0.2−4.0−0.9−1.6−0.3−0.2−0.0−0.0−0.0
Debt repaid————−0.10————
Shares issued—————130r0r0—
Cash from financing activities91182022212114286.64.1
Change in cash4.3−13−8.0−4.5−1.014−5.6141.90.9
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Hyperion Defi, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Digital Assets$1 M98%
  • Ophthalmic Technology$0 M1.8%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Hyperion Defi, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$9.3 M
Other top executives, average
$2.0 M
the CEO earned 4.7× this
$100 invested is now
$89
Hyperion Defi, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$9.3 M$4.6 M$2.0 M$89
2024Chief executive$808 K$510 K$413 K$4
2023Chief executive$775 K$1.2 M$626 K$52

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Hyperion Defi, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 2 · Auditor changed 1 · Directors and officers 8 · Material agreement 6 · Agreement ended 1 · New debt 2 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 9

Hyperion Defi, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Agreement endedResults announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Bylaws or fiscal year changedResults announced8-K
Directors and officersUnregistered share sale8-K
Material agreement8-K
Results announced8-K
Directors and officersMaterial agreement8-K
Directors and officers8-K
Directors and officers8-K
Material agreement8-K
Delisting noticeDirectors and officers8-K
Shareholder rights changedShareholder vote8-K
Results announced8-K
Directors and officersBylaws or fiscal year changed8-K
Directors and officersMaterial agreementNew debtUnregistered share saleBylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Delisting notice8-K
Auditor changed8-K
Results announced8-K
Material agreementNew debt8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Hyperion Defi, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$50 MPrivate placement after listing$50 to $250 million5equity, optionsSEC
Mar 2020$6 MPrivate placement after listing$2 to $10 million82equity, optionsSEC
Jul 2017$6 MNo. 2$2 to $10 million10equity, optionsSEC
Jul 2016$4 MNo. 1$2 to $10 million4equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Hyperion Defi, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2024
Latest
—
2024-11-15
Hyperion Defi, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
Hyperion Defi, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
50% of workforceRestructuring planSEC 8-K“The Company is implementing a reduction in force affecting approximately 50% of its workforce.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Hyperion Defi, Inc. compares in Biotechnology

  • Market cap$52 M · higher than 27% of 726
  • Revenue$2 M · higher than 30% of 647
  • Net margin-985.0% · higher than 0% of 408
  • Revenue growth1250.0% · higher than 98% of 438
  • Price / sales26.1× · lower than 26% of 339
  • Price / book1.3× · lower than 73% of 534
  • FCF yield-58.0% · higher than 21% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Hyperion Defi, Inc.🇺🇸$52 M—-985.0%+1250.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 9, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, value.today research, SEC filing.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Hyperion Defi, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Hyperion Defi, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Hyperion Defi, Inc.? Suggest a correction